Episode 3 | Racing Against Resistance: The Future of Antimicrobial Innovation
Rienk Pypstra, tranScrip’s Chief Medical Officer, joins Marc Lemonnier, Chief Executive Officer of Antabio, to discuss the global threat of antimicrobial resistance. They’ll explore why innovation must outpace bacterial evolution, how economic incentives can sustain antibiotic R&D, and why agility, collaboration, resilience and strategic vision are essential to overcoming resistance and driving the future of AMR.
--------
23:00
--------
23:00
Episode 2 | Getting Ready for Clinic
Rob Fox, tranScrip’s Chief Commercial Officer, joins Dr Christopher Floyd, Executive Medical Director, Early Development, to discuss the leap from preclinical to clinical. They’ll explore why it’s critical to weave a compelling translational narrative, design adaptive first-in-human studies, treat regulators as partners, focus on clarity over clutter in data, avoid decision paralysis and build expert teams aligned for success from day one.
--------
26:00
--------
26:00
Episode 1 | The Biotech Blueprint
Dr Rienk Pypstra, tranScrip’s CMO, joins David Findlay, CEO of Rostra Therapeutics, to lay out the essential blueprint for biotech success. They’ll explore why it’s vital to define a laser-focused vision & mission, build an early Target Product Profile, win investor confidence with a data-driven route to market, engage regulators from day one and select partners who add real value.
Welcome to tranScrip Talks, the podcast for biotech and pharma companies seeking strategic, practical, and expert-led guidance across the entire product lifecycle, from TRANslation to preSCRIPtion. Brought to you by the experts at tranScrip, each episode explores the most pressing challenges and breakthrough opportunities across early and clinical development, market access and commercialisation, regulatory and medical affairs, pharmacovigilance and more.
Expect real case experience, actionable insights and forward-thinking strategies, all designed to help you accelerate and optimise the path from molecule to market.
Portugal